Risk factors of type 1 gastric neuroendocrine neoplasia 
in patients with chronic atrophic gastritis. A retrospective, 
multicentre study

Campana, Davide; Ravizza, Davide; Ferollà, Piero; Faggiano, Antongiulio; Grimaldi, Franco; Albertelli, Manuela; Ricci, Claudio; Santini, Donatella; Brighi, Nicole; Fazio, Nicola; Colao, Annamaria; Ferone, Diego; Tomassetti, Paola

doi:10.1007/s12020-016-1099-y

Cited by 33 publications

(17 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…91 Patients with high grade chronic atrophic gastritis have an increased concentration of gastrin in plasma and occasionally show development of type 1 gastric neuroendocrine and carcinoid tumors, though hypergastrinemia is considered not to be a sufficient condition for the progression from hyperplasia to dysplasia of ECL cells. 92,93 Gastric carcinoid tumors are divided into 3 types, type 1 with hypergas- Figure 2. Acid-inhibition related adverse events reported during proton pump inhibitor administration.…”

Section: Gastric Neuroendocrine Tumormentioning

confidence: 99%

Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use

Kinoshita

Ishimura

Ishihara

2018

J Neurogastroenterol Motil

197

172

View full text Add to dashboard Cite

Proton pump inhibitors (PPIs) potently inhibit gastric acid secretion and are widely used for treatment of acid-related diseases including gastroesophageal reflux disease and secondary prevention of aspirin/NSAID-induced ulcers. Although clinically important adverse effects of PPIs can occur, just as with other drugs, those are not frequently observed during or after administration. Thus, PPIs are regarded as relatively safe and considered to be clinically beneficial. Recently, PPIs have become frequently administered to patients with functional gastrointestinal diseases or primary prevention of drug-related gastroduodenal damage, even though their beneficial effects for those conditions have not been fully confirmed. PPIs tend to be given for conditions in which the necessity of the drug has not been clarified, thus otherwise rare adverse effects are presented as clinically relevant. Although several PPI-related adverse effects have been reported, their clinical relevance is not yet clear, since the evidence reported in those studies is not at a high enough level, as the majority are based on retrospective observational studies and the reported hazard ratios are low. It is important to administer PPIs only for patients who will gain a substantial clinical benefit and to continue to investigate their adverse effects with high quality prospective studies.

show abstract

Section: Gastric Neuroendocrine Tumormentioning

confidence: 99%

Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use

Kinoshita

Ishimura

Ishihara

2018

J Neurogastroenterol Motil

197

172

View full text Add to dashboard Cite

show abstract

“…[3][4][5][6]9 Patients with Types I or II tumours typically have long-lasting or even lifelong hypergastrinaemia and significantly elevated serum gastrin levels. [31][32][33][34][35][36] For example, the median value of serum gastrin is approximately 10-fold above the upper normal limit in patients with chronic gastritis. [33][34][35] In contrast, in most PPI users, the magnitude of hypergastrinaemia is modest, with a median value of threefold of the upper normal limit.…”

Section: Discussionmentioning

confidence: 99%

Gastric neuroendocrine tumours from long‐term proton pump inhibitor users are indolent tumours with good prognosis

Trinh

Shi

2020

Histopathology

View full text Add to dashboard Cite

Gastric neuroendocrine tumours from long-term proton pump inhibitor users are indolent tumours with good prognosis Aims: Proton pump inhibitors (PPIs) are among the most widely used medications in the United States. Most PPI users have persistent hypergastrinaemia during treatment. However, gastric neuroendocrine tumours diagnosed in long-term PPI users are rarely reported. Their clinicopathological features and prognosis are not characterised. It remains unclear whether or not they can be classified as Type III sporadic tumours. Methods and results: We retrospectively characterised 66 gastric neuroendocrine tumours from patients without atrophic gastritis and gastrinoma from two tertiary care medical centres, including 38 tumours in patients who had used PPIs for at least 1 year and 28 tumours from patients without long-term PPI use (control group, Type III tumours). Compared to controls, tumours from long-term PPI users tended to be in the pT1-2 category (98% versus 79%, P = 0.09) and less often invaded the serosa (3% versus 18%, P = 0.08) or lymphovascular spaces (11% versus 32%, P = 0.06). Using Kaplan-Meier analysis, longterm PPI users had significantly longer overall survival than controls (P = 0.035). While three control patients developed distant metastasis and seven died, long-term PPI users were without distant metastasis (P = 0.06) or death (P = 0.002) during follow-up. However, five long-term PPI users developed additional gastric neuroendocrine tumour(s), while none of the controls did (P = 0.07). Conclusions: Our results show that gastric neuroendocrine tumours of long-term PPI users are probably less aggressive compared to Type III sporadic tumours and have an indolent disease course. Our findings support the classification of gastric neuroendocrine tumours in long-term PPI users as a separate subtype.

show abstract

“… 18 , 19 A multicenter, retrospective study showed that male sex, chromogranin A (CgA) > 61 U/L, and intestinal metaplasia were independent risk factors for type 1 g-NETs in patients with CAG. 20 …”

Section: Discussionmentioning

confidence: 99%

A Prospective and Retrospective Clinical Controlled Observation of Chinese Herbal Decoction (SMLJ01) for Type 1 Gastric Neuroendocrine Tumors

et al. 2020

View full text Add to dashboard Cite

Introduction: Type 1 gastric neuroendocrine tumors (g-NETs) have a good prognosis but a high recurrence rate. Aim: To observe the clinical efficacy of the treatment of type 1 g-NETs with the Chinese herbal decoction SMLJ01. Materials and Methods: A prospective and retrospective, clinical, controlled observation was conducted in 4 Chinese centers from 2012 to 2019. Patients with type 1 g-NETs were nonrandomly divided into treatment and control groups after endoscopic treatment based on herbal treatment administered according to their wishes. The treatment group received oral SMLJ01, with follow-up every 6 to 12 months, while the control group received follow-up alone. Patient follow-up (via telephone) from 2012 to 2017 was mainly retrospective. All patients after 2017 were followed prospectively. The recurrence times and rates were compared after treatment for at least 6 months. Symptom improvements were evaluated in the treatment group. The follow-up ended on October 31, 2019. Results: During a median follow-up of 22 months (range: 2-86 months), the survival rate was 100%, and no metastases occurred. Twenty-one of the 82 treated patients (25.6%) had recurrence after a median of 22 months, and 22 of the 54 control patients (40.7%) had recurrence after a median of 8 months ( P = .063). The Kaplan-Meier curve analysis showed that the patients in the treatment group had a significantly longer median recurrence-free survival (RFS) time than those in the control group ( P = .001). The risk of recurrence in the treatment group was 0.38 relative to that in the control group (95% CI: 0.20-0.70). The symptom score of the patients after taking Chinese medicine was 19.5 (10.3, 28.0), which was significantly lower than before treatment (31.5 (19.3, 38.0)). The difference was statistically significant ( P < .01). Conclusion: SMLJ01, with the effects of soothing the liver, strengthening the spleen, increasing acid and harmonizing the stomach, may help reduce the recurrence rate, relieve symptoms and prolong the recurrence time in patients with type 1 g-NETs and is worthy of evaluation with further randomized research with large sample sizes and longer follow-up periods.

show abstract

Risk factors of type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis. A retrospective, multicentre study

Cited by 33 publications

References 25 publications

Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use

Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use

Gastric neuroendocrine tumours from long‐term proton pump inhibitor users are indolent tumours with good prognosis

A Prospective and Retrospective Clinical Controlled Observation of Chinese Herbal Decoction (SMLJ01) for Type 1 Gastric Neuroendocrine Tumors

Contact Info

Product

Resources

About